AzTrials
AzTrials

Fresnel PrismNCT07531667

Fresnel Prism in Low Vision Patients With Homonymous Hemianopia Defect in Cipto Mangunkusumo Hospital

A study testing Fresnel prism in people with Fresnel Prism, run by Universitas Indonesia at 1 site in Indonesia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Homonymous hemianopia is a visual field defect that causes functional disabilities, such as decreased self-confidence, limited mobility, and increased risk of falls. Studies related to the effectiveness and comfort of Fresnel prisms, especially in the Indonesian population are limited. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Fresnel Prism
What is being tested?
Fresnel prism
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
25 participants
Where
1 siteIndonesia
Study dates
1 May 2022to 1 Aug 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • subjects with a diagnosis of partial or complete homonymous hemianopia based on the results of the Humphrey perimetry examination;
  • age 18 years or older;
  • corrected visual acuity of 6/18 or better; and
  • willing to give consent for this study and consistently follow the rehabilitation process.

Who cannot join

  • ocular motility disorders; the primary position of the eyeball was not orthophoric; and
  • walking disorders that resulted in poor fixation of glasses.

Trial locations and contacts

1 site in 1 country.

Indonesia1 site
  • Department of Ophthalmology, Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo Hospital, Indonesia

    Jakarta, DKI Jakarta, 14430

Other trials in Indonesia

About this study

Official title: Use of Fresnel Prism in Low Vision Patients With Homonymous Hemianopia Defect in Cipto Mangunkusumo Hospital

Background: Homonymous hemianopia is a visual field defect that causes functional disabilities, such as decreased self-confidence, limited mobility, and increased risk of falls. Studies related to the effectiveness and comfort of Fresnel prisms, especially in the Indonesian population are limited.

Objective: To evaluate the effectiveness and comfort level of Fresnel prisms in expanding visual field in an Indonesian patient population with homonymous hemianopia.

Read the detailed description

: Fresnel prisms with a power of 40∆ were fitted to the patient's spectacles for two weeks. Visual field parameters were analysed using the Humphrey Field Analyzer with the SITA 24-2 algorithm, while the Pelli-Robson and ETDRS charts were used to assess contrast sensitivity and visual acuity, respectively. After visual assessment, comfort was quantitatively assessed using a comfort scale.

Conditions
Fresnel Prism
Being tested
Fresnel prism
Keywords
homonymous hemianopia, fresnel prism, visual field impairment
Medical subject headings
Hemianopsia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fresnel prismDevice

    The Fresnel prism chosen was of 40∆ power (the largest size available) with the aim of the largest visual field expansion, which was 20 degrees that the patient felt during environmental orientation and mobilisation. Fresnel prism fitting was performed using the patient's spectacles (if wearing spectacles) or plano glasses provided by the researcher. The patient was given object movement stimulation to identify the visual field boundary and the Fresnel prism was placed 2 mm away from the healthy visual field area. The Fresnel prism was placed on the inner side of the lens. Vertical correction was performed in homonymous hemianopia depending on the visual field defect. The patient was then asked to practice scanning before being asked to wear the Fresnel prism for 5.5 hours daily for two weeks. Patients were given a wear sheet to evaluate the duration of wear in a day.

Study groups in NCT07531667
Study groupRoleWhat they receive
Fresnel prismExperimentalThe Fresnel prism chosen was of 40∆ power (the largest size available) with the aim of the largest visual field expansion, which was 20 degrees that the patient felt during environmental orientation and mobilisation. Fresnel prism fitting was performed using the patient's spectacles (if wearing spectacles) or plano glasses provided by the researcher. The patient was then asked to practice scanning before being asked to wear the Fresnel prism for 5.5 hours daily for two weeks. Patients were given a wear sheet to evaluate the duration of wear in a day
Receives: Device: Fresnel prism

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Visual Fied

    Mean Deviation (dB) Pattern Standard deviation (dB) Visual field index (%)

    Measured: 2 weeks

Secondary outcomes (2)
  1. TPDK

    Sharp vision with correction (log mar)

    Measured: 2 weeks

  2. Contrast sensitivity

    Contrast sensitivity (log units)

    Measured: 2 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Apr 2026
  2. Study start1 May 2022
  3. Primary completion1 Jul 2022
  4. Study completion1 Aug 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
25 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07531667
Sponsor's protocol ID
23-06-0925
Other IDs
PUTI Saintekes 2020 Grant
Status last verified
May 2022
First submitted
9 Apr 2026
Last updated
15 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: IPD will not be shared due to patient privacy considerations

Questions about this trial

What is this clinical trial studying?

A study testing Fresnel prism in people with Fresnel Prism, run by Universitas Indonesia at 1 site in Indonesia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Visual Fied (time frame: 2 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in